Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cladribine With Simultaneous or Delayed Rituximab in Hairy Cell Leukemia
NCT00923013Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2008
- Primary completion
- Jul 2024
- Countries
- 1
01
Overview
A Phase 2 trial of cladribine, rituximab in hairy cell leukemia (HCL), sponsored by National Cancer Institute. Started Oct 2008; status: active, not recruiting.
02
Drugs
cladribinerituximab
03
Conditions
hairy cell leukemia (HCL)
Beyond the preview
Go deeper on NCT00923013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00923013.